Stock Track | DIAGENS-B Soars 22.29% in Morning Session After Securing World-First Medical AI Certification

Stock Track05-26

DIAGENS-B's stock price surged 22.29% during the morning trading session on Tuesday, marking a significant upward movement for the healthcare technology company.

The sharp increase followed the company's announcement that its self-developed AI AutoVision® chromosome karyotype assisted diagnosis software has officially received a Class III Medical Device Registration Certificate from China's National Medical Products Administration. This certification covers chromosome analysis for prenatal diagnosis and assisted reproduction applications.

According to the company, this represents the world's first Class III medical device registration certificate for chromosome karyotype analysis with L3-level anomaly recognition capabilities, and it's also the first such certificate obtained based on large model technology. The board stated that this regulatory approval reflects official recognition of the safety, effectiveness, and clinical value of their iMedImage® medical imaging large model technology.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172628570?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172628570","market":"hk","top_or_hot":-1,"title":"Stock Track | DIAGENS-B Soars 22.29% in Morning Session After Securing World-First Medical AI Certification","media":"Stock Track","content":"<p>DIAGENS-B's stock price surged 22.29% during the morning trading session on Tuesday, marking a significant upward movement for the healthcare technology company.</p><p>The sharp increase followed the company's announcement that its self-developed AI AutoVision® chromosome karyotype assisted diagnosis software has officially received a Class III Medical Device Registration Certificate from China's National Medical Products Administration. This certification covers chromosome analysis for prenatal diagnosis and assisted reproduction applications.</p><p>According to the company, this represents the world's first Class III medical device registration certificate for chromosome karyotype analysis with L3-level anomaly recognition capabilities, and it's also the first such certificate obtained based on large model technology. The board stated that this regulatory approval reflects official recognition of the safety, effectiveness, and clinical value of their iMedImage® medical imaging large model technology.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | DIAGENS-B Soars 22.29% in Morning Session After Securing World-First Medical AI Certification</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | DIAGENS-B Soars 22.29% in Morning Session After Securing World-First Medical AI Certification\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-26 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DIAGENS-B's stock price surged 22.29% during the morning trading session on Tuesday, marking a significant upward movement for the healthcare technology company.</p><p>The sharp increase followed the company's announcement that its self-developed AI AutoVision® chromosome karyotype assisted diagnosis software has officially received a Class III Medical Device Registration Certificate from China's National Medical Products Administration. This certification covers chromosome analysis for prenatal diagnosis and assisted reproduction applications.</p><p>According to the company, this represents the world's first Class III medical device registration certificate for chromosome karyotype analysis with L3-level anomaly recognition capabilities, and it's also the first such certificate obtained based on large model technology. The board stated that this regulatory approval reflects official recognition of the safety, effectiveness, and clinical value of their iMedImage® medical imaging large model technology.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02526","symbol_name":"德适-B","start_time":0,"source_url":"","article_id":"1172628570","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172628570","pubTimestamp":1779760850,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"DIAGENS-B's stock price surged 22.29% during the morning trading session on Tuesday, marking a significant upward movement for the healthcare technology company.The sharp increase followed the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02526":"德适-B"},"translate_title":"个股追踪|DIAGENS-B获全球首个医疗AI认证早盘大涨22.29%","themeId":"02981a1241dc45d438f6686ffcbd3101","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02526":1},"content_text":"DIAGENS-B's stock price surged 22.29% during the morning trading session on Tuesday, marking a significant upward movement for the healthcare technology company.The sharp increase followed the company's announcement that its self-developed AI AutoVision® chromosome karyotype assisted diagnosis software has officially received a Class III Medical Device Registration Certificate from China's National Medical Products Administration. This certification covers chromosome analysis for prenatal diagnosis and assisted reproduction applications.According to the company, this represents the world's first Class III medical device registration certificate for chromosome karyotype analysis with L3-level anomaly recognition capabilities, and it's also the first such certificate obtained based on large model technology. The board stated that this regulatory approval reflects official recognition of the safety, effectiveness, and clinical value of their iMedImage® medical imaging large model technology.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172628570","isCrawlerRequest":true}